Reactions Weekly

, Volume 1633, Issue 1, pp 11–11 | Cite as

Spironolactone + renin-angiotensin drugs: MHRA clarification

News item
  • 49 Downloads

Reference

  1. Medicines and Healthcare products Regulatory Agency (UK). Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia - clarification. Drug Safety Update 10: 4, No. 5, Dec 2016. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/577417/pdf_Dec.pdf Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Personalised recommendations